Repurposing capacity for Covid-19 vaccine, say Indian pharma firms

Bharat Biotech, whose vaccine candidate Covaxin is undergoing clinical trials, said vaccine makers are either repurposing capacities that they have for other products or redirecting upcoming capacities for new products
As clinical trials for a Covid-19 vaccine get underway, Indian pharma companies are either repurposing existing capacity or sacrificing capacity for new vaccine products under development.

Speaking at the Confederation of Indian Industry’s Life Science Conclave 2020, Suresh Jadhav, executive director of the Serum Institute of India (SII), said the biotechnology company has already put in place an expansion plan for new products in the pipeline. “Around half a dozen new products are under development. These typically take five to seven years until the product is licensed,” he said. Therefore, SII can use this capacity to make Covid-19 vaccines now. 

Jadhav further added that the institute will need to ramp-up capacities for new products if the demand for a Covid-19 vaccine persists. Should demand for the vaccine dwindle, it will continue to use this enhanced capacity for other products.

He pointed out that this is also the first time the Government of India has given permission to build a stockpile when conducting clinical trials.

SII is the largest vaccine manufacturer in the world in terms of the number of doses it produces. It has the wherewithal to manufacture 1.8-1.9 billion doses of the bulk drug, from the existing 1.6 billion doses of life-saving biologicals it manufactures.

The Pune-based manufacturer of immunobiological drugs has entered into multiple international collaborations for the Covid-19 vaccine. It is expanding capacity to 1.9 billion doses of the vaccine to treat SARS-CoV-2 disease by the end of this year.

Bharat Biotech, whose vaccine candidate Covaxin is undergoing clinical trials, said vaccine makers are either repurposing capacities that they have for other products or redirecting upcoming capacities for new products to make way for the Covid-19 vaccine.

Sai Prasad, president of quality operations of Bharat Biotech, further added that the biotechnology company headquartered in Hyderabad is in talks with middle- and high-income countries for procurement of their vaccines. This will ensure the requisite funding for vaccine development, he said. “Funding research in the absence of push funding (during the research phase) or pull contracts (assurance to buy a certain quantity at a stipulated price) is a challenge,” said Prasad.

Indian Immunologicals (IIL), a Hyderabad-based biopharmaceutical company, is working on its Covid-19 candidate based on a live attenuated virus model. It has set up a 200-milion-doses-per-annum facility for drug products, and is building a manufacturing facility for drug substances, said Anand Kumar, managing director of IIL. Drug substances are used to make vaccines. These can be whole bacterial cells, viruses, parasites, antigens, etc.

 “All these are multi-product facilities. No one will set up a dedicated facility for one product,” clarified Kumar.

The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred — one, get a high price for the product (which again may deprive many from getting a jab), and two, have the government buy a few hundred million doses of the product at a certain price. “For a vaccine player to take a risk of Rs 200-300 crore for a new product development can seem a daunting task in the absence of any assurance,” said one Indian vaccine maker.  


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel